^
4d
Trial completion • Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 amplification • PGR negative
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • QL1209 (pertuzumab biosimilar)
6d
ATREZZO: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=55, Recruiting, SOLTI Breast Cancer Research Group | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date • Combination therapy • Tumor mutational burden • Metastases
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • vinorelbine tartrate
6d
Trial initiation date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 overexpression • ER negative • PGR negative
|
carboplatin • docetaxel • Perjeta (pertuzumab)
7d
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative • PGR negative
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • HLX11 (pertuzumab biosimilar)
8d
Phase classification • Combination therapy • BRCA Companion diagnostic • PARP Companion diagnostic • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative
|
PD-L1 IHC 22C3 pharmDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
carboplatin • gemcitabine • nadunolimab (CAN04)
11d
NKT3447-101: A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=90, Recruiting, NiKang Therapeutics, Inc. | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> May 2025 | Trial primary completion date: Jan 2027 --> Mar 2025
Enrollment open • Trial completion date • Trial primary completion date • Metastases
12d
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 expression
|
gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
12d
GPR39-mediated ERK1/2 signaling reduces permethrin-induced proliferation of estrogen receptor α-negative cells. (PubMed, Ecotoxicol Environ Saf)
Knockdown of GPR39 partially impeded permethrin-induced cellular proliferation and altered the expression of proliferation marker protein PCNA and cell cycle-associated protein cyclin D1 via the ERK1/2 signaling pathway. These findings offer novel evidence for permethrin as an environmental breast cancer risk factor, displaying its potential to impact breast cancer cell proliferation via an estrogen receptor-independent pathway.
Journal
|
ER (Estrogen receptor) • CCND1 (Cyclin D1) • CHI3L1 (Chitinase 3-like 1) • PCNA (Proliferating cell nuclear antigen)
|
ER negative • CCND1 expression • PCNA expression
13d
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer (clinicaltrials.gov)
P1, N=22, Completed, Barbara Parker, MD | Active, not recruiting --> Completed | Phase classification: P1b --> P1
Trial completion • Phase classification • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
|
paclitaxel • zilovertamab (UC-961)
15d
Trial completion date • Surgery
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Tecentriq (atezolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin
15d
SerMa: Seroma of the Mammary Gland (clinicaltrials.gov)
P=N/A, N=2000, Recruiting, University Hospital Augsburg | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER positive + PGR positive • PGR positive • PGR negative
15d
New P1/2 trial • Metastases
|
Keytruda (pembrolizumab) • carboplatin • azenosertib (ZN-c3)
15d
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (clinicaltrials.gov)
P2, N=99, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR positive • PGR negative
18d
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (clinicaltrials.gov)
P2, N=58, Active, not recruiting, National Cancer Institute (NCI)
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • PGR negative
|
azacitidine • Jingzhuda (entinostat)
18d
New trial • Metastases
19d
Strong Protection by 4-Hydroxyestrone against Erastin-Induced Ferroptotic Cell Death in Estrogen Receptor-Negative Human Breast Cancer Cells: Evidence for Protein Disulfide Isomerase as a Mechanistic Target for Protection. (PubMed, Biochemistry)
In conclusion, this study demonstrates that 4-OH-E1 is a novel inhibitor of PDI and can strongly inhibit ferroptosis in human breast cancer cells in an estrogen receptor-independent manner. The mechanistic understanding gained from the present study may also aid in understanding the estrogen receptor-independent cytoprotective actions of endogenous estrogen metabolites in many noncancer cell types.
Journal
|
ER (Estrogen receptor)
|
ER negative
|
erastin
22d
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. (clinicaltrials.gov)
P1/2, N=75, Recruiting, Massachusetts General Hospital | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • PGR negative
|
Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)
27d
HER2-low Unresectable and/or Metastatic Breast Cancer in Russia (clinicaltrials.gov)
P=N/A, N=2450, Recruiting, AstraZeneca | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • PTEN mutation + HR positive
29d
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=33, Recruiting, University of Washington | Trial completion date: Apr 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma)
|
HER-2 negative • HER-2 expression • PGR expression
|
EP-101 STEMVAC • Leukine (sargramostim)
29d
High rate of high-risk human papillomavirus among benign and breast cancer patients in Ethiopia. (PubMed, PLoS One)
This study did not find a significant difference in HPV expression between breast cancer and non-malignant breast tumors; however, the higher percentage of HPV in ER-positive compared to ER-negative breast cancer warrants further attention.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
1m
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer (clinicaltrials.gov)
P2, N=1008, Recruiting, Fudan University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification • HR negative • PGR expression
|
tamoxifen • capecitabine • Irene (pyrotinib) • exemestane
1m
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) (clinicaltrials.gov)
P2, N=356, Recruiting, Fudan University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR expression • PGR negative
|
Herceptin (trastuzumab) • tamoxifen • capecitabine
1m
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=30, Active, not recruiting, G1 Therapeutics, Inc. | Trial primary completion date: Jun 2023 --> Nov 2023
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • ER negative • PGR negative
|
Trodelvy (sacituzumab govitecan-hziy) • Cosela (trilaciclib)
1m
GeparDouze: Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo (clinicaltrials.gov)
P3, N=1550, Active, not recruiting, NSABP Foundation Inc | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Surgery
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Tecentriq (atezolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin
1m
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=11, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
1m
Trial completion • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Keytruda (pembrolizumab) • doxorubicin hydrochloride • letrozole • anastrozole • exemestane
1m
H-43432: Sitravatinib in Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, C. Kent Osborne, MD | Terminated --> Withdrawn
Trial withdrawal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12)
|
sitravatinib (MGCD516)
1m
Targeting the Cell Cycle, RRM2 and NF-κB for the Treatment of Breast Cancers. (PubMed, Cancers (Basel))
Here, we report that didox, an inhibitor of ribonucleotide reductase in combination with palbociclib, can overcome palbociclib resistance in ER-positive and ER-negative breast cancers. Our current study also reports that the CCND1 and RRM2 upregulation associated with palbociclib-resistant breast cancers decreases upon ribonucleotide reductase inhibition. Our data present a novel and promising biomarker-driven combination therapeutic approach for the treatment of ER-positive and ER-negative breast cancers that involves the inhibition of the CDK4/6-cyclinD1/pRb cell cycle axis that merits further clinical investigation in human models.
Journal
|
ER (Estrogen receptor) • CCND1 (Cyclin D1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
ER positive • ER negative
|
Ibrance (palbociclib) • didox (NSC-324360)
1m
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs (clinicaltrials.gov)
P2, N=58, Recruiting, Sarah Sammons, MD | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Dec 2023
Enrollment open • Trial initiation date
|
datopotamab deruxtecan (DS-1062a)
2ms
Differential expression of chemokine genes by race and Breast Cancer Consensus Subtypes in hormone receptor positive breast cancer (AACR 2024)
Our findings show that AAW with HR+ breast cancer have tumors with more inherently aggressive molecular subtypes associated with poor prognosis compared to EAW. These results also further support the premise that HR+/HER2- tumors are highly heterogeneous and strongly suggest that chemokine gene expression is associated with breast cancer subtype.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • CCR3 (C-C Motif Chemokine Receptor 3) • CCR6 (C-C Motif Chemokine Receptor 6) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • ACKR1 (Atypical Chemokine Receptor 1) • ACKR4 (Atypical Chemokine Receptor 4)
|
HR positive • HER-2 negative • ER negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
2ms
Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial (AACR 2024)
Chemotherapy-free neoadjuvant regimen with DTP in HER2-enriched EBC showed high pathologic response rates comparable to that with chemotherapy. This DTP regimen may provide an effective, relatively non-toxic, and biologically driven alternative to standard of care chemotherapy in this HER2-enriched subset of EBC.
P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 positive • ER negative • PGR negative
|
BluePrint
|
Herceptin (trastuzumab) • Imfinzi (durvalumab) • Perjeta (pertuzumab)
2ms
Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study (AACR 2024)
The PACE study (NCT03147287) enrolled patients (pts) with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) MBC after progression on CDK4/6 inhibitor (CDK4/6i) and endocrine therapy, and randomized pts to fulvestrant (ful) alone; ful with palbociclib; or ful, palbociclib, and avelumab [Mayer et al., SABCS 2022]. Future analyses are needed to investigate the correlation between ER expression levels on CTCs with survival and treatment response. This, together with information about the mutational status of ESR1 by ctDNA sequencing, might provide a new perspective on the development of resistance to ful and CDK4/6i in HR+/HER2- MBC.
P2 data • PD(L)-1 Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HR positive • HER-2 negative • ER negative • ER expression
|
CELLSEARCH®
|
Ibrance (palbociclib) • Bavencio (avelumab) • fulvestrant
2ms
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (clinicaltrials.gov)
P2, N=348, Not yet recruiting, West German Study Group | Initiation date: Dec 2023 --> Apr 2024
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
2ms
Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer. (PubMed, Cancer Lett)
In contrast, in HR-negative breast cancer, the HER2-low group displayed a higher frequency of PIK3CA mutations and PI3K pathway alterations. These findings offered valuable insights for the precise targeted treatment of HER2-low breast cancer in different HR statuses.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • GATA3 (GATA binding protein 3)
|
BRCA2 mutation • HR positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • GATA3 mutation
2ms
Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade. (PubMed, Cancers (Basel))
In this retrospective study, 348 patients with HER2-positive breast cancer who received NAST with docetaxel and carboplatin, combined with trastuzumab and pertuzumab (TCHP), were included. Conversely, in ER-positive cases, low ER expression, HER2 IHC 3+, and numerical TIL levels or high TIL levels emerged as independent predictors of pCR. Our results suggest that ER expression, HER2 protein expression, and TIL levels serve as valuable predictors of the treatment response to neoadjuvant TCHP.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 expression • ER negative • EGFR positive
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
2ms
Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients. (PubMed, Cancers (Basel))
Our results also demonstrated a decrease in CD8+ and CD4+ T cell infiltration in high-PIEZO1 HR-negative tumors. Further investigations are necessary to elucidate the mechanistic roles of PIEZO1 in HR-negative breast cancer.
Clinical data • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
HR positive • HR negative
2ms
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer (clinicaltrials.gov)
P2, N=28, Terminated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | N=73 --> 28 | Recruiting --> Terminated; The sponsor has adjusted its R&D strategy.
Enrollment change • Trial termination • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Duoenda (mitoxantrone liposomal)
2ms
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
LN-145
2ms
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MUC16 (Mucin 16, Cell Surface Associated)
|
HER-2 negative • PGR expression
|
gemcitabine • Elahere (mirvetuximab soravtansine-gynx)
2ms
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer (clinicaltrials.gov)
P1/2, N=29, Active, not recruiting, Providence Health & Services | Phase classification: P2 --> P1/2
Phase classification
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Keytruda (pembrolizumab) • paclitaxel • capecitabine
2ms
Increased matrix stiffness enhances pro-tumorigenic traits in a physiologically relevant breast tissue- monocyte 3D model. (PubMed, Acta Biomater)
We present a biologically relevant 3D-model for studies of human dense breasts, providing a platform for investigating both biophysical and biochemical properties that may affect cancer progression. This model will have a major scientific impact on studies for identification of novel targets for breast cancer prevention.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
2ms
IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
P1/2, N=29, Recruiting, University of Florida | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024 | Suspended --> Recruiting
Enrollment open • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 negative • HR negative + HER-2 positive
|
Tecentriq (atezolizumab) • Fotivda (tivozanib)